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Abstract 
It is well known, that the pharmaceutical industry is struggling with increasing 
cost and length of R&D projects. Earnings of a drug drop drastically after patent 
expiration. Thus, the industry spends much effort on reducing Time-to-Market. 
In the literature, little attention is given to drug launching activities after the 
drug has been approved. In this paper, we present a recourse-based stochastic 
model, which allows for time phasing the market entries to balance the 
fluctuating demand with the fixed and periodic production of the active 
pharmaceutical ingredient. The two major risk elements during launch are 
forecasting inaccuracy and the risk of a required label change from local 
regulatory authorities. Robust solutions are found by implementing the Robust 
Optimization framework. 
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1. Introduction 
The process of launching a new drug is receiving a lot of attention from the 
pharmaceutical companies as they are under pressure to launch new drugs faster 
to counter the increasing R&D cost. To help solve this issue three distinct 
planning problems related to introduction of new products have been identified 
in [1]; planning (1) the portfolio of investigational new drugs, (2) the capacity 
level which will satisfy future requirements, and (3) the production of the drug. 
The first two planning problems include the uncertainty of obtaining an 
approval for the drug. Here attention is given to the two main activities after the 
approval is obtained; the preparation of the supply chain for the launch and the 
negotiations to determine sales price and subsidies with local authorities. First, 
supply chain preparations are necessary due to the fixed and periodic supply of 
the active pharmaceutical ingredient, which is insufficient to supply the initial 
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surge for the drug required to fill the entire downstream supply chain. Secondly, 
it is required that negotiations are carried out with local authorities before  
entering a market, since packaging material has to be approved and subsidies 
and sales prices negotiated. 
Two central risks influence operations. First, the demand forecast uncertainty 
for a new drug is very large. The drug manufacturer has to determine a balance 
between investing in inventory and the risk of supply shortage, which is 
difficult to overcome due to the limited flexibility of the production processes. 
Secondly, the regulatory authorities can demand changes in the packaging 
material. As a result, any finished i.e. packaged products on inventory have to 
be scrapped. It cannot be repackaged. A pharmaceutical company has to decide 
on, whether to place the stock further upstream; see the divergent supply chain 
in figure 1 (a). That would reduce the scrapping risk but increase the Time-to-
Market [TTM]. Alternatively, the company can focus on short TTM by 
packaging the product prior to the negotiations; aptly called risk packaging 
because of the risk for scrapping the packaged products.  
In our approach we handle both risk elements by use of stochastic program with 
recourse for the six scenarios for each market seen in figure 1 (b). . In 
programming with recourse, variables are divided into design variables, which 
are independent of the uncertain parameter and control variables, which allow 
for corrective measures as the uncertain data becomes known. Since production 
must be planned ahead, flow variables before and at the packaging site are 
design variables; see figure 1 (a). The remaining downstream variables are 
control variables. It is assumed that both uncertainties are revealed 
simultaneously. A good review of the recourse terminology is given in [2]. 
Solving a program with recourse gives the best expected solution, but may lead 
to solutions that are highly vulnerable to scenarios with a large downside. 
Managers in the pharmaceutical industry are often risk averse and prefer stable 
solution despite reduced expected profit. To get solutions that are less sensitive 
to variations in the uncertain parameter, [3] developed a Robust Optimization 
framework. By penalizing the objective function with the variance of the 
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solution, solutions are found where the objective function value stays close to 
the expected solution despite variations in the uncertain parameter. In [4] the 
framework is applied to a planning model of a network of chemical processes. 
 
2. Model Formulation 
Due to space limitation we only present key equations from the MILP model. 
The sets used are m M for markets, t T  for time and s S  for scenarios.  
 
2.1. Market Access and Market Launch Constraints 
Equations 1 – 3 below are used for time phasing market launches, lmt, and 
starting the reimbursement negotiation, cmt. The drug can be launched only once 
in each market according to Eq. 1. Eq. 2 forces reimbursement negotiations with 
length Nm to be completed before a launch. Eq. 3 limits the number of 
negotiations carried out at any given time to reflect resource limitation on e.g. 
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2.2. Supply Chain Flow Constraints 
The inventory balance in Eq. 4 is the only supply chain flow constraints shown 
here. Here the added scrap variable, scmts, is needed for the scenarios in which a 
label change is required, forcing the company to dispose of the finished product 
inventory. rmts is the amount of products required given the demand. immts and 
pmmt are the market specific amounts of inventory and packaged drug 
respectively, as the drug becomes market specific in the packaging stage. 
, 1,  , ,m t s mmts m ts mtstim pm r im m Ms s Sc t T  	   	    (4) 
 
2.3. Scrap Constraint 
The scrap variable from Eq. 4 is set through Eq. 5. The variable is the same as 
the inventory on hand after the previous period, only if the reimbursement 
negotiations are just concluded in t i.e. started Nm periods before and the 
scenario prescribes a label change via IPms. Here K is a large number. 
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2.4. Objective Function 
The profit as given in Eq. 6 is to be maximized, where  ms(lmt, immts, scmts) is the 
cash flow as a function of (i) the revenue of sales given lmt, (ii) the holding cost 
given immts plus the upstream inventory and (iii) the scrapping cost given scmts. 
Lms denotes the probability of each scenario for each market. 
1 1
max ( , , )
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L l im sc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  (6) 
All continuous variables are positive and inventory variables and flow variables 
describing packaged quantities have limited capacity. The design variables 
presented here are (cmt, lmt, pmmt) and the control variables are (immts, scmts, rmts). 
 
2.5. Inclusion of Robust Optimization 
The model presented above is a typical MILP model with recourse. This 
solution is exposed to scenarios with potential low profit or even loss. To reflect 
risk aversion, the Robust Optimization framework from [3] is implemented. 
Here Eq. (7) is added to Eq. (6), since profit should be maximized: 
' '
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 is a weight, which can be set freely and is a measure of the risk aversion. 
Higher equals higher penalty in the objective function and reflects higher risk 
aversion. Eq. 7 penalizes the effect of radical scenarios with the difference 
between the scenario and the expected solution.  ms used in [5] ensures that the 
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Presentations of the Restricted Recourse framework and model robustness have 
been omitted due to the lack of space. Please refer to [4] and [3], respectively. 
 
3. Illustrative Example 
Data has been created to reflect a realistic case study, which includes 10 
markets over a 30 period time horizon. In figure 2 markets covered for both the 
Market Launch Planning model [MLP] i.e. including equations 1 to 6 and the 
Robust Market Launch Planning model [RMLP] i.e. including equations 1 to 8 
can be seen. Here delays are gaps between completion of negotiations and 
market launch. The risk aversion weight, , is set to 1. As the approval of the 
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drug is given in period 12, negotiation cannot start before. After period 17, no 
new markets are entered for either model as ramp up of capacity follows the 
increase in demand. 
 Figure 2: Illustration of selected markets and delay between launch and negotiation completion. 
As can be seen, the main difference in the solutions is that RMLP launches the 
drug in more and smaller markets and awaits the outcome of the negotiations in 
the larger markets 4 and 5. The profit for both solutions is almost the same, 
while revenue is reduced less than 1 % for RMLP compared to MLP. In the 
RMLP solution, the expected scrap is reduced by 33 %, though holding cost 
rises 13 % compared to MLP. The percentage of total inventory held at the 
upstream stocking point only increases less than 1 % for the RMLP, since more 
inventory of packaged drug is held to supply more markets. In the RMLP model 
the variance and maximum deviation are reduced 31 % and 28 % respectively 
compared to the MLP model. Computation time is 26 seconds and 39 seconds 
for the MLP and the RMLP, respectively. 
 
4. Conclusion and Further Work 
We presented a modeling approach for planning market launches of new 
pharmaceutical products, which included a robust opimization framework. The 
model was tested for a case to illustrate its effectiveness. Future work will focus 
on linking the modeling approach to capacity planning and production planning. 
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